FDA clears first-of-its-kind trial to see if CRISPR gene editing can cure HIV
The FDA has cleared a company attempting to use CRISPR gene-editing to cure HIV to begin clinical trials.
Article from Endpoints News
Rite Aid Corp. to move HQ to Philadelphia Navy Yard
Rite Aid Corp. signed a lease for a 23,500 square foot space at 1200 Intrepid Ave for their “enterprise headquarters” as part of an effort to redefine how they envision their employees working as a result of the pandemic.
Article from Philadelphia Business Journal
Penn spinout led by veteran pharma execs emerges from stealth mode, raises $50M to advance gene-editing technology
Director of the University of Pennsylvania’s gene therapy program, Dr. James Wilson, has formed a company specializing in gene editing.
Article from Philadelphia Business Journal
Engineering CAR T Cells to Deliver Endogenous RNA Wakes Solid Tumors to Respond to Therapy
A new study from Penn Medicine demonstrates a naturally occurring RNA can activate the body’s own natural T cells to seek out cancer cells that may have escaped recognition by CAR T cells.
Article from Penn Medicine
Renovacor, Inc. Closes Its Business Combination with Chardan Healthcare Acquisition 2 Corp. and Will Begin Trading on the New York Stock Exchange
Renovacor, Inc. will begin trading on the New York Stock Exchange under ticket symbols “RCOR” and “RCOR.WS”, respectively.
Article from Business Wire
Investments in Philadelphia startups are setting records. These investors think the boom is here to stay.
With the increase of private equity deals, angel investing, and venture capital raises, experts believe spending on startups will continue in the year 2022.
Article from Philadelphia Business Journal
Cambridge Innovation Center to double its lab space in University City with $11M expansion
Cambridge Innovation Center is set to create one the largest shared laboratory hubs in the country with its expansion of its lab space in University City.
Article from Philadelphia Business Journal
INOVIO Doses First Participant in Phase 2 Trial for its DNA Vaccine Against Middle East Respiratory Syndrome (MERS), a Coronavirus Disease
A biotechnology company has announced the start of Phase 2 trial in the development of the first vaccine against MERS.
Article from PR Newswire
Drexel’s tech talent ranks among MIT, Carnegie Mellon on new report
Drexel University coders rank high on a new report assessing talent in tech.
Article from Philadelphia Business Journal